期刊
JOURNAL OF NEUROLOGY
卷 257, 期 11, 页码 1917-1923出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-010-5779-x
关键词
Relapsing-remitting multiple sclerosis; Glatiramer acetate; Copaxone; Subcutaneous injections; Local injection site reactions; Injection pain
资金
- Teva Neuroscience, Kansas City, MO
- Teva Neuroscience
- Glaxo Smith Kline
- Biogen Idec
- Johnson and Johnson
- Eli Lilly
- Genzyme
- Opexa
- Merck
- Supernus
- Boehringer Ingelheim
- Janssen
- Elan
- Pfizer
- Bayer Health Care
- Bayer
- EMD Serono
- Forest
- Novartis
- EMD Serono Pharmaceuticals
- Opexa Therapeutics
- Ono
- Sanofi-Aventis
Daily glatiramer acetate (GA) 20 mg/1.0 mL is a first-line treatment for relapsing-remitting multiple sclerosis (RRMS). To reduce the occurrence of injection pain and local injection site reactions (LISRs), a reduced volume formulation of GA was developed. This study compared pain and LISRs after injecting the marketed and the novel formulations. RRMS patients currently injecting GA participated in this multicenter, randomized, crossover comparative study. All patients administered once-daily subcutaneous injections of GA 20 mg/1.0 mL (marketed formulation) or GA 20 mg/0.5 mL (reduced volume formulation) for 14 days. Patients were crossed-over to the alternate treatment for an additional 14 days. Using a Visual Analog Scale (VAS), patients recorded in daily diaries the severity of injection pain immediately and 5 min post-injection, and the presence and severity of LISRs (swelling, redness, itching, lump) within 5 min and 24 h post-injection. VAS pain scores were ranked significantly lower immediately and 5 min after GA 20 mg/0.5 mL injections (p < 0.0001). Although LISRs were rare for both preparations, the severity of reactions ranked significantly lower and fewer symptoms occurred within 5 min and 24 h of using the reduced volume formulation (p < 0.0001). GA injected subcutaneously in a reduced volume formulation is a more tolerable option.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据